Retatrutide 10mg
Triple Incretin Agonist Showing 24% Weight Loss in Phase 2 Trials
Retatrutide is the first triple GLP-1/GIP/glucagon receptor agonist in development, achieving unprecedented 24% body weight reduction in Phase 2 trials — the highest ever recorded for a pharmaceutical weight loss agent. It combines the GLP-1/GIP dual agonism of Tirzepatide with glucagon receptor activation for additional metabolic and energy expenditure benefits.
Triple Incretin Agonist Showing 24% Weight Loss in Phase 2 Trials
Retatrutide (LY3437943) adds glucagon receptor agonism to dual incretin activation, increasing energy expenditure, promoting hepatic fat clearance (critical for NASH), and further amplifying weight loss beyond dual agonism. Phase 2 data shows 24.2% weight loss at 48 weeks — setting a new benchmark.
As one of the most studied compounds in the metabolic & fat loss research space, Retatrutide has attracted sustained scientific interest across Next-generation obesity research, Triple incretin mechanism studies, NASH/fatty liver research. Peer-reviewed evidence indicates that 24.2% weight loss at 48 weeks in Phase 2, which has positioned Retatrutide as a reference standard for researchers exploring next-generation obesity research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Retatrutide Documented Benefits: 4 Documented Mechanisms
Unprecedented Weight Loss
24% body weight reduction in Phase 2 — highest recorded for any investigational weight loss agent.
Triple Receptor Mechanism
GLP-1R + GIPR + GCGR activation adds glucagon-driven energy expenditure to incretin appetite suppression.
NASH Potential
Glucagon receptor activity drives hepatic fat clearance, showing promise for fatty liver disease.
Energy Expenditure Increase
Glucagon component increases metabolic rate, distinguishing retatrutide from dual agonists.
How Retatrutide Works: Molecular Mechanism & Pathway
Triple GLP-1R/GIPR/GCGR agonist; GLP-1R for appetite/insulin, GIPR for metabolic enhancement, GCGR for increased energy expenditure and hepatic fat oxidation.
The 4 primary research pathways identified for Retatrutide — Unprecedented Weight Loss, Triple Receptor Mechanism, NASH Potential — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that highest weight reduction ever recorded in pharmaceutical trials, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Retatrutide's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Retatrutide is routinely studied alongside Tirzepatide and Retatrutide in metabolic & fat loss-focused compound panels. Researchers investigating next-generation obesity research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that nASH liver improvement alongside weight loss has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Retatrutide research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- 24.2% weight loss at 48 weeks in Phase 2
- Highest weight reduction ever recorded in pharmaceutical trials
- NASH liver improvement alongside weight loss
Ideal For
- Next-generation obesity research
- Triple incretin mechanism studies
- NASH/fatty liver research
- Energy expenditure studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Retatrutide. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
24.2% weight loss at 48 weeks in Phase 2
Highest weight reduction ever recorded in pharmaceutical trials
NASH liver improvement alongside weight loss
Third-Party Verified Every Batch
Each vial of Retatrutide is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
